Compass Therapeutics (CMPX) Gains from Investment Securities (2019 - 2026)

Compass Therapeutics has disclosed Gains from Investment Securities across 8 years of filings, most recently posting $489000.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $489000.0, down 89.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (down 77.26% YoY), and the FY2025 annual result was $16.4 million, up 164.04% from the prior year.
• Gains from Investment Securities came in at $489000.0 for Q1 2026 at Compass Therapeutics, up from $399000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $17.2 million in Q3 2025 to a low of -$70000.0 in Q4 2022.
• The 5-year median for Gains from Investment Securities is $2.5 million (2025), against an average of $4.0 million.
• Across the five-year window, Gains from Investment Securities tumbled 112.12% in 2022 and surged 137231.68% in 2023, its largest moves.
• Compass Therapeutics' Gains from Investment Securities stood at -$70000.0 in 2022, then jumped by 150.0% to $35000.0 in 2023, then soared by 174.29% to $96000.0 in 2024, then surged by 315.62% to $399000.0 in 2025, then advanced by 22.56% to $489000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $489000.0 (Q1 2026), $399000.0 (Q4 2025), and $17.2 million (Q3 2025), per Business Quant data.